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Introduction
Motor unit number estimate (MUNE) quantization seems
to be the most reliable procedure for measuring the loss of
motor neurons in clinical trials.1–4 In the perspective of
new clinical trials of promising drugs intended for patients
with amyotrophic lateral sclerosis (ALS), longitudinal
studies are essential. MUNE techniques might therefore
provide a useful approach.
Since 1971,5 various procedures have been proposed for
calculating MUNE. All these techniques rely on the same
basic principle. The MUNE is determined through division
of the supramaximal compound muscle action potential
(CMAP) size by the average surface motor unit potential
(SMUP) size. Average SMUP size estimates can be made by
measuring all-or-nothing responses at threshold stimula-
tion,5–7 by recording single motor unit (MU) F-waves,8
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METHOD: The adapted multiple point
stimulation (AMPS) method for calculating
motor unit numbers (MUNE) was applied
in 12 patients with amyotrophic lateral
sclerosis (ALS) before riluzole therapy (T0)
and again after 4, 8 and 12 months of
treatment.
RESULTS: Paired Student’s t-test indicated
a signicant decrease of thenar MUNE
and compound muscle action potential
(CMAP) size at each 4-monthly interval,
while average surface motor unit poten-
tial (SMUP) size did not change signi-
cantly over time. The rate of motor unit
(MU) loss at month 4 was more than 20%
in six patients (group 1) and less than
20% in six other patients (group 2). Com-
parison of groups 1 and 2 by Mann-
Whitney U-testing indicated that percent
changes in thenar MUNE and CMAP size
compared to baseline were signicantly
different at months 4, 8 and 12, while no
difference between the two groups was
found for average SMUP size variations. In
the group with a slow rate of MU loss,
CMAP size remained stable, while in the
group with a rapid rate of MU loss, there
was a dramatic reduction in size of the
CMAP. A positive correlation was found
between percent change in thenar MUNE
at T4 and at T12 (P < 0.001).
CONCLUSION: AMPS is a useful technique
to document MUNE, SMUP size and CMAP
size changes over time in patients with
ALS. (ALS 2002; 3: 31–38)
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from spike-triggered averaging9 or from measurements of
CMAP variance.10 In the present study, the adapted mul-
tiple point stimulation (AMPS) method was chosen.7,11
AMPS is a simple, non-invasive, painless, rapidly executed
procedure, which does not require any specic recording
system or software. This method is thus easily applicable
in routine clinical use. In addition, AMPS seems to be
devoid of methodological bias.
The current study was designed, over a period of one
year, to analyse thenar MUNE and the size of the remain-
ing MU and CMAP variations by using the AMPS method
in patients with ALS.
Patients and methods
Participants
Data were collected from 20 consecutive patients with ALS
after having obtained their informed consent. These
patients underwent motor and sensory nerve conduction
measurements in upper and lower limbs bilaterally, and
concentric needle recordings from at least three limbs,
including the thenar muscles where MUNE were obtained.
All patients fullled the clinical and electrophysiological
criteria for denite ALS.12 Moreover, patients were screened
to exclude any additional pathology affecting peripheral
nerves, muscles or neuromuscular junctions. We excluded
carpal tunnel entrapment neuropathy on the basis of clini-
cal examination and electrophysiological tests (motor con-
duction velocity with terminal latency index and palmar
stimulation of sensory bres). None received drug therapy
initially, in particular riluzole; but all patients received
riluzole after the rst electrophysiological and clinical eval-
uation (T0).
AMPS was performed on the right side or, if amyotro-
phy was present at baseline, on the side with the lesser
thenar atrophy. AMPS was applied at baseline T0 and after
4, 8 and 12 months of a riluzole therapy (T4, T8, T12).
MUNE, average SMUP size and CMAP size were measured
in all patients at T0 and each 4-month interval. With a view
to normalizing the results, percent changes compared to
baseline were calculated for the three variables using the
following formula:
[(T0 value-control visit value) / T0 value] 3 100.
Results in patients were also compared with those from 70
healthy control subjects of both sexes and ages ranging
from 19 to 93 years. As the three variables studied depend
on age, each patient’s result was assessed by comparing it
with the normal limits in terms of age.7,13
Thirteen patients with ALS completed this study over
the one-year period. Four patients died (two died 9 and 11
months after the onset of symptoms); three patients were
lost to follow-up for unknown reasons; one additional
patient was eliminated because of missing data. The results




AMPS was originally designed for median-innervated
thenar muscles. The stigmatic and reference recording elec-
trodes consisted of silver foil 4 cm long by 0.8 cm wide.
The stigmatic electrode was positioned transversely over
the thenar eminence, as close as possible to the muscle
endplates. The reference electrode was attached over the
proximal phalanx of the thumb. The ground electrode
(silver foil) was xed over the dorsum of the wrist. In this
longitudinal study, a meticulous replication of electrode
placement was sought by measuring in each patient the
precise distance between the stimulating electrode and the
tip of the thumb. The stimulating electrodes (Medelec
Model LBS 53051; interelectrode distance: 2.5 cm) were
moved over the median nerve from the wrist to the elbow
with the cathode distal.
Stimulation and recording systems
All studies were performed on a Nicolet Viking IV EMG
machine (Nicolet Instrument Corp.). SMUP and com-
pound motor responses were recorded with a gain of
50–100 µV/division and were evoked by constant-current
square stimuli of 0.05 ms duration, at a rate of 1 Hz, with
a weak intensity gradually increased from a subthreshold
value by incremental steps of 0.1–0.5 mA. CMAP were
evoked by stimuli of 0.2 ms duration at a rate of 1 Hz,
stimulating electrodes placed 7 cm proximal to the stig-
matic electrode (supramaximal intensity was dened as
150% of the stimulus intensity giving a maximal
response). Surface recordings were ltered with a
20 Hz–5 kHz bandpass. The hand temperature was main-
tained above 30°C.
Description of the AMPS method
AMPS was a two-step procedure. The rst step consisted of
estimating the MU size by collecting and averaging 10
well-identied SMUP after stimulation at distinct points
along the course of the median nerve between the wrist
and the elbow. At each stimulation site, only two or three
SMUP were successively evoked by incremental stimula-
tion. The second step consisted of eliciting CMAP by
supramaximal stimulation of the median nerve at the wrist
7 cm from the stigmatic electrode. By dividing the CMAP
size by the average SMUP size, a MUNE was obtained.
Each SMUP was randomly incorporated in the estima-
tion. However, to avoid alternation and ensure that any
increment of the motor response corresponded to the acti-
vation of one single MU, some specic criteria had to be
met. SMUP had to be evoked :
 with distinct thresholds
 in an all-or-nothing fashion
 with no fractioning of the compound motor responses
to successive identical stimuli
 in an orderly and reproducible manner.
Except for the rst SMUP evoked at each selected stimu-
lation point, the precise morphology of successive SMUP
was not visualized, the overall potential representing, as it
did, two or three units. It was theoretically possible to
record the same SMUP twice from two different stimula-
tion points in any one trial because their morphology
might not be recognizable. To ensure that selected SMUP
were different, the morphology of an individual SMUP
could be reconstructed by subtracting from each com-
pound motor response the preceding one obtained from
the same stimulus site with a lower intensity. This recon-
struction took place automatically when point-by-point
differences were measured between successive digitized
traces.
SMUP were eliminated from the estimation in the
following circumstances: similar morphology at two dis-
tinct stimulation points, SMUP which did not full selec-
tion criteria, and predominantly positive SMUP, as they
were supposed to be elicited from distant muscles, such as
lumbrical muscles.
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Results
The clinical data and results of longitudinal testing for the
12 patients with ALS are shown in Table 1. In addition,
analyzes were also performed on two subsets of six
patients: patients 1–6 with a rate of MU loss at T4 of more
than 20% (group 1), and patients 7–12 with a rate of MU
loss at T4 of less than 20% (group 2) (Tables 1 and 2,
Figure 1).
Age, sex and disease duration
Mean ages of the 12 patients with ALS were: 54.8 6 9.9 years
(range: 36–69); 52.8 6 10.4 years in group 1; and
56.8 6 10.0 in group 2. There was no signicant difference
between the mean ages of groups 1 and 2. There were four
men and two women in each group. The overall mean
disease duration (from the onset of symptoms) at baseline
T0 was 21.2 6 9.0 months. In group 1, the mean disease
duration was 20.5 6 9.7 months and in group 2, 21.8 6 9.2
months. There was no signicant difference between the
two  groups.
Thenar muscle involvement
At baseline, clinical thenar amyotrophy was present in ve
of 12 patients with ALS: two in group 1 (33%) and three
in group 2 (50%). After one year of riluzole therapy,
thenar amyotrophy was observed in 10 of 12 ALS patients:
six in group 1 (100%) and four in group 2 (66%).
Needle electromyography (EMG) of the thenar muscles
using a standard concentric needle indicated chronic motor
denervation (brillation potentials in fewer than four of 10
needle muscular insertions, and increased size of MU poten-
tial) in eight patients with ALS: three in group 1 (50%) and
ve in group 2 (84%). Subacute motor denervation (brilla-
tion potentials in more than four of 10 needle muscular
insertions and increased size of MU potential) was observed
in three patients from group 1 (50%) and none from group
2 (0%). In patient 7 (group 2), there was no EMG evidence
of thenar muscle involvement.
Thenar MUNE
At baseline T0, thenar MUNE was decreased in all patients
with ALS (Table 1). Mean thenar MUNE in the 12 patients
were 38.5 6 25.5 at T0, 29.8 6 23.8 at T4, 23.8 6 21.1 at
T8 and 15.3 6 18.4 at T12 (Table 1). Paired Student’s t-test
indicated a signicant decrease of thenar MUNE at each 4-
monthly interval (Table 2).  Among the four patients who
died before month 12 (patients withdrawn from the
longitudinal analysis), two presented a very high rate of
MU loss (>50% at T4). At T12, the percent change compared
to baseline reached on average 60.8% (Table 1). Compari-
son of group 1 (rate of MU loss more than 20% at T4) and
group 2 (rate of MU loss less than 20% at T4) by Mann-
Whitney U-testing indicated that percent changes com-
pared to baseline were signicantly different at T4, T8 and
T12 (Table 2).
Average SMUP size
Average SMUP size remained within normal limits in
patient 7 at T0, patients 6 and 8 at T8, and patient 8 at T12;
while all other average SMUP size values were above the
upper limit of normal (Table 1). Mean average SMUP sizes
in the 12 patients with ALS were 357 6 162 µV.ms at T0,
391 6 204 µV.ms at T4, 334 6 202 µV.ms at T8 and
336 6 217 µV.ms at T12 (Table 1). Comparison of different
means obtained at T0, T4, T8 and T12 by using paired
Student’s t-test did not indicate any signicant difference
(Table 2).
Comparison by Mann-Whitney U-testing of percent
changes at T4, T8 and T12 (compared to baseline) did not
show any signicant difference between group 1 and
group 2 (Table 2).
CMAP size
Thenar CMAP size remained within normal limits in seven
patients with ALS at T0 (four from group 1 and three from
group 2), ve patients at T4 (two from group 1 and three
from group 2), three patients (from group 2) at T8 and two
patients (from group 2) at T12; and was decreased in other
patients (Table 1). Mean thenar CMAP sizes in the 12
patients were 11.6 6 7.1 mV.ms at T0, 9.4 6 6.5 mV.ms at
T4, 6.7 6 5.8 mV.ms at T8 and 4.4 6 5.0 at T12 (Table 1).
Paired Student’s t-test indicated a signicant decrease of
thenar CMAP size at each 4-monthly interval (Table 2).
Comparison of group 1 and group 2 by Mann-Whitney
U-testing indicated that percent changes compared to base-
line were signicantly different at T4, T8 and T12 (Table 2). 
In group 1, the percent decline in CMAP size reached
on average 95.5% over a one-year period. In group 2,
CMAP size remained quite stable till month 8, and at
month 12, the percent change in CMAP size was on
average 47.3 % (Table 1).
Relationship between variables
Correlation coefcients between percent changes, com-
pared to baseline T0, in the three variables derived by using
AMPS are shown in Table 3. Changes in thenar MUNE
were correlated with changes in CMAP size but were not
correlated with changes in average SMUP size. The latter
was correlated with changes in CMAP size only when vari-
ations at month 4 in both variables were compared.
Percent changes in thenar MUNE or CMAP size calcu-
lated during distinct AMPS evaluations over time were cor-
related; while no correlation was found concerning
changes in average SMUP size.
Figure 1 shows the positive correlation between the rate
of MU loss at T4 and the rate of MU loss at T12. The six
patients with a rate of MU loss greater than 20% at T4
(group 1) had a rate of MU loss of more than 50% at T12.
Five of the six patients with a rate of MU loss less than 20%
at T4 (group 2) had a rate of MU loss less than 50% at T12.
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First of all, the reliability and practicality of AMPS will be
discussed.
Assumptions related to the MU recruitment by
incremental stimulation
SMUP selection criteria were established to avoid alterna-
tion. We could therefore postulate that any increment of
the motor response was due to activation of an additional
MU.
The sample of selected MU had to be representative of
the whole population. Theoretically, techniques using
incremental stimulation or near threshold SMUP activa-
tion might all be biased toward large MU.14 However, the
arguments developed by McComas and colleagues,5 Galea
and colleagues15 and Doherty and Brown6 are evidence
against this possible bias. Moreover, considering the size
distribution of SMUP evoked by techniques using incre-
mental stimulation, a wide distribution with more small
units than large ones was observed. This distribution was
also nearly identical to those obtained by techniques in
which MU were not recruited at threshold intensity as in
the F-response method,8 or procedures using a MU recruit-
ment based on voluntary contraction9 or techniques esti-
mating the MU size by measuring the MU twitch.16
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Variables Paired Student’s t-test
Thenar MUNE 38.5 6 25.5 (T0) 29.8 6 23.8 (T4) p < 0.02
(n 5 12) 29.8 6 23.8 (T4) 23.8 6 21.1 (T8) p < 0.02
23.8 6 21.1 (T8) 15.3 6 18.4 (T12) p < 0.02
Average SMUP size (µV.ms) 357 6 162 (T0) 391 6 204 (T4) NS
(n 5 12) 391 6 204 (T4) 334 6 201 (T8) NS
334 6 201 (T8) 336 6 217 (T12) NS
357 6 162 (T0) 336 6 217 (T12) NS
CMAP size (mV.ms) 11.6 6 7.1 (T0) 9.4 6 6.5 (T4) p < 0.05
(n 5 12) 9.4 6 6.5 (T4) 6.7 6 5.8 (T8) p < 0.05
6.7 6 5.8 (T8) 4.4 6 5.0 (T12) p < 0.05
MU loss > 20% at T4 MU loss < 20% at T4 Mann-Whitney
patients 1–6 patients 7–12 U-test
Thenar MUNE variation 2 37.2 6 11.8 (T4) 2 10.3 6 6.4 (T4) p < 0.001
compared to baseline (%) 2 53.7 6 17.9 (T8) 2 22.5 6 12.5 (T8) p < 0.001
2 79.0 6 11.1 (T12) 2 42.5 6 16.6 (T12) p < 0.001
Average SMUP size variation 2.4 6 23.8 (T4) 13.2 6 14.9 (T4) NS
compared to baseline (%) 2 8.4 6 32.3 (T8) 2 4.3 6 38.4 (T8) NS
2 8.5 6 24.4 (T12) 2 3.5 6 44.7 (T12) NS
CMAP size variation 2 35.9 6 18.2 (T4) 1.1 6 11.5 (T4) p < 0.002
compared to baseline (%) 2 61.5 6 12.3 (T8) 2 25.5 6 30.1 (T8) p < 0.05
2 95.5 6 14.2 (T12) 2 47.3 6 23.2 (T12) p < 0.02
MUNE 5 motor unit number estimate; SMUP5 surface motor unit potential; CMAP5 compound muscle action potential; MU5 motor unit; 
T4, T8, T12 5 evaluation by using the adapted multiple point stimulation method after 4, 8 and 12 months of riluzole therapy.
Table 2


































Percent change at T4 compared to T0
Figure 1
Relationship between the rate of motor unit loss at month 4 and the rate of
motor unit loss at month 12 in 12 patients with amyotrophic lateral sclerosis.
Percent change (compared to baseline) in thenar motor unit number esti-
mate (MUNE) at T4 was more than 20% in 6 patients (circles, group 1) and
was less than 20% in 6 other patients (dots, group 2).
Validity
AMPS results were reproducible in control subjects as well
as in patients with motor denervation. In 10 normal sub-
jects, when thenar MUNE and average SMUP size estima-
tion by the AMPS method were repeated by the same
examiner on two successive days, the coefcients of varia-
tion between results from the two trials were 10.4 % and
9.5 % respectively.7 In patients with ALS, when AMPS was
performed twice in the same session with new electrode
placements for the second trial, the coefcient of variation
for both MUNE and average SMUP size was 4% between
the two trials.11
Ease of application
AMPS was a fast procedure, which could be completed in
about 15 minutes. Moreover, AMPS did not require any
specic recording system or software. Thus, AMPS was
easily applicable for clinical purposes. With the AMPS
technique, it was possible to obtain a MUNE in all 70 vol-
unteers studied,13 without technical failures. Moreover, in
our experience with patients presenting with severe axonal
loss, particularly in the 12 patients with ALS in the current
study, MUNE were easier to obtain than in healthy volun-
teers. Indeed, as previously reported,17 there was less
overlap of MU thresholds when denervation was severe,
and alternation was therefore less noticeable. On the other
hand, in partially denervated muscles the accuracy is also
higher, since the sample of units is a greater fraction of the
whole population. When the MU number was very low, it
was sometimes possible to evoke more than three SMUP
without alternation from the same point using incremen-
tal stimulation. Therefore, two or three different stimula-
tion points along the course of the median nerve were
enough to derive a MUNE. If there were less than 10 MU
remaining in some patients, the best way to derive a
MUNE was sometimes to nd one stimulation point from
which it was possible to activate the few remaining MU
without alternation. In these particular cases, AMPS was
very similar to the initial estimation technique described
by McComas and colleagues.5
Finally, AMPS was non-invasive and painless, as only
surface electrodes and low stimulation intensities were
used.
Thenar MUNE
At baseline T0, after a mean disease duration of 21.2 6 9.0
months, all 12 patients with ALS had decreased thenar
MUNE compared with the normal limits in terms of age
previously dened7,13 in a group of 70 healthy control sub-
jects. In patient 7, there was neither thenar amyotrophy
nor electromyographic evidence of motor denervation in
thenar muscles (Table 1). Thus, in patients with ALS,
decreased MUNE was probably one of the most sensitive
signs of motor denervation. Paired Student’s t-test pointed
out a signicant decrease of thenar MUNE every 4 months
(Table 2). After one year, the MUNE decline reached on
average 60.8% compared to baseline (Table 1). A more
severe evolution has been found by several authors, who
established that on average the MU population halved in
each 6–month period, with a drop of around 75% in the
rst year after diagnosis.11,18,19 This might be due to the fact
that only patients who survived one year after baseline
were included in the study. Two patients, with an acute
form of ALS, presented very high rate of MU loss (>50% at
T4), and died before T12, and were therefore withdrawn
from analysis.
Two subsets of six patients were dened on the basis of
the rate of MU loss at T4, more (group 1) or less (group 2)
than 20% compared to baseline. From a statistical point of
view, these two groups did not differ in terms of age,
disease duration from the onset of symptoms and sex.
Comparison by Mann-Whitney U-testing of percent
changes in thenar MUNE compared to baseline indicated a
signicant difference between both groups at each 4-
monthly interval (Table 2). In group 1, with a rapid rate of
progression, there was thenar wasting in two patients at T0,
but in all six at T12, and EMG recordings at baseline in the
six patients revealed thenar motor denervation which was
chronic (n5 3) or subacute (n5 3). In group 2, with a
slower rate of progression, there was thenar wasting in
three patients at T0 and in four at T12. Thenar muscle EMG
data at baseline remained normal in one patient and indi-
cated chronic motor denervation in ve (Table 1).
Average SMUP size
Associated with the reductions in thenar MUNE was the
enlargement of surviving units, as indicated by the increase
in average SMUP sizes measured in all 12 patients, with
the exception of patient 7 at T0, patient 6 at T8 and patient
8 at T8 and T12 (Table 1). The smallest SMUP recorded in
the 12 patients with ALS was 35 µV.ms and the largest was
2738 µV.ms. No difference was observed between average
SMUP size results estimated in all 12 patients with ALS by
repeated AMPS testing at 4-monthly intervals. In addition,
there was no statistical difference between percent changes
compared to baseline calculated from both subsets of six
patients (Table 2). These data were probably indicative of
the fact that the patients were not at the same stage of evo-
lution and that several parameters inuenced the MU size
in different ways. Among these parameters, the following
ones had to be considered: 1. collateral reinnervation,
which was probably more effective in the early stages, and
small MU loss increased the average SMUP size; 2. the dis-
appearance of some large units and the MU ‘disinteg-
ration’ phenomenon, which might occur in terminal
stages,11,20 decreased the mean MU size.
CMAP Size
Values of CMAP size conrmed that collateral reinnerva-
tion is able, from an electrophysiological point of view, to
compensate for motor denervation. In fact, at the time of
the rst examination (T0), seven of 12 patients kept their
thenar CMAP size within normal limits. However, among
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the four patients from group 1 (rate of MU loss more than
20% at T4) in whom CMAP size remained within normal
limits at T0, only two kept this variable within the normal
range at T4, and none at T8 and T12. Conversely, in the
three patients from group 2 (rate of MU loss at T4 less than
20%), in whom CMAP size was within normal limits at T0,
the variable remained quite unchanged at T4 and T8, and
even up to one year after diagnosis in two patients (Table
1). Consequently, Mann-Whitney U-testing indicated that
percent changes, compared to baseline, were signicantly
different between groups 1 and 2 at T4, T8 and T12 (Table
2).
Relationships between variables
CMAP size is the product of MUNE and average SMUP
size. Correlations between changes in thenar MUNE and
CMAP size (Table 3) were therefore expected. However,
change in average SMUP size was correlated with change
in CMAP size only at T4 (Table 3). We can thus postulate
that CMAP size variations over time were more inuenced
by MUNE than by average SMUP size variations. On the
other hand, CMAP size variations over time might be due
to a change in the placement of recording electrodes,
which should induce similar changes in average SMUP
size. It seems that it was not the case in the present study,
since both variables were poorly correlated. As indicated
under ‘Patients and Methods’, in this longitudinal study a
meticulous replication of recording electrode placement
was sought by measuring in each patient the precise dis-
tance between the stigmatic electrode and the tip of the
thumb.
The relationship between different values from the
same variable, measured over time, might be a way to
determine the prognostic value of the variable under
analysis. From this point of view, the best correlation coef-
cient, between results at T4 and T12 (the most distant
percent change evaluations), was found for change in
thenar MUNE (r 5 0.71) (Table 3). This correlation was
indicative of a quite stable rate of MU loss over the one-
year period; hence, the percent change in MUNE at T4
might be considered a prognostic value of the rate of MU
loss at T12. Figure 1 shows that in group 1, the rate of MU
loss at T12 compared to baseline was more than 50%,
while ve of six patients from group 2 presented a rate of
MU loss less than 50%. These data give substance to the
prognostic value of percent change in thenar MUNE at T4
over a short follow-up period. Nevertheless in longer
follow-up, Dantes and McComas18 and Daube21 found
that the initial, usually rapid, loss of MU was followed by
a slower loss of the remaining MU. In the present study,
patients with ALS were not at the same stage of evolution.
In fact, some patients were in the initial phase of the
disease (i.e. patient 7 at T0: thenar MUNE 5 72, disease
duration 5 9 months) and some others in a later phase
(i.e. patient 11 at T0: thenar MUNE 5 3, disease
duration 5 28 months).
Conclusion
With a view to clinical trials, it should be useful to be able
to distinguish patients with ALS according to a rapid or a
slow rate of progression. Besides brillation abundance,
shape variability of MU potentials, decremental response
to repetitive nerve stimulation22 and bre density,4 MUNE
techniques might be useful for this. Results obtained by
AMPS, a simple, reliable, and painless method, suggest
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Thenar MUNE Average SMUP size CMAP size
T4 T8 T12 T4 T8 T12 T4 T8 T12
Thenar T4 / 0.92
1 1 1 0.711 0.12 0.01 0.03 0.821 1 0.761 0.62°
MUNE T8 / / 0.721 0.03 0.22 0.15 0.69°° 0.721 0.69°°
T12 / / / 0.28 0.12 0.04 0.70°° 0.51 0.811 1
Average T4 / / / / 0.32 0.16 0.66°° 0.16 0.29
SMUP size T8 / / / / / 0.54 0.13 0.50 0.28
T12 / / / / / / 0.11 0.58 0.51
CMAP size T4 / / / / / / / 0.65° 0.63°
T8 / / / / / / / / 0.811 1
T12 / / / / / / / / / /
MUNE 5 motor unit number estimate; SMUP5 surface motor unit potential; CMAP5 compound muscle action potential; 
T4, T8, T12 5 evaluation by using the adapted multiple point stimulation method after 4, 8 and 12 months of riluzole therapy.
° 5 P < 0.05, °° 5 P < 0.02, 1 5 P < 0.01, 1 1 5 P < 0.002, 1 1 1 5 P < 0.001
Table 3
Correlation coefcients (r) between percent changes (compared to baseline) in AMPS variables
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that slow progression is characterized by a rate of MU loss
of less than 20% every four months and stable CMAP size,
and conversely for rapid progression.
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